financetom
Business
financetom
/
Business
/
ESAB beats Q2 sales estimates, adjusted EPS meets expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ESAB beats Q2 sales estimates, adjusted EPS meets expectations
Aug 6, 2025 3:54 AM

Overview

* ESAB ( ESAB ) Q2 sales rise 1% to $716 mln, beating analysts' expectations, per LSEG data

* Adjusted EPS for Q2 meets analyst estimates, per LSEG data

* Co achieved record core adjusted EBITDA margin of 20.1%

Outlook

* ESAB ( ESAB ) raises 2025 core sales growth outlook to 1.5%-3.5% from (1.0)% to 1.5%

* ESAB ( ESAB ) now expects 2025 core organic sales growth of 0.0% to 2.0%

* ESAB ( ESAB ) raises 2025 core adjusted EBITDA outlook to $525 mln-$535 mln

* ESAB ( ESAB ) increases core adjusted EPS guidance to $5.15 to $5.30

Result Drivers

* ROBUST DEMAND - Strong demand in EMEA and APAC regions supported sales growth, per CEO Shyam P. Kambeyanda

* TARIFF NAVIGATION - Americas team managed tariff-related pressures using EBX

* STRATEGIC ACQUISITIONS - Acquisitions of DeltaP, Aktiv, and EWM expected to enhance portfolio and drive future growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $716 mln $685.80

mln (6

Analysts

)

Q2 Meet $1.36 $1.36 (7

Adjusted Analysts

EPS )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

* Wall Street's median 12-month price target for ESAB Corp ( ESAB ) is $142.50, about 7.3% above its August 5 closing price of $132.03

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
New Gold to Acquire Remaining 19.9% Stake in Canada Gold Mine
New Gold to Acquire Remaining 19.9% Stake in Canada Gold Mine
Apr 7, 2025
07:08 AM EDT, 04/07/2025 (MT Newswires) -- New Gold ( NGD ) said Monday it has agreed to acquire the remaining 19.9% free cash flow interest in Canada's New Afton Mine from the Ontario Teachers' Pension Plan for $300 million in cash. The acquisition will bring New Gold's ( NGD ) interest in New Afton to 100%, the company said....
Volkswagen's Audi holding cars in U.S. ports due to autos tariff
Volkswagen's Audi holding cars in U.S. ports due to autos tariff
Apr 7, 2025
BERLIN, April 7 (Reuters) - Volkswagen's Audi is holding back cars that arrived in U.S. ports after April 2 because of the newly imposed 25% autos tariff, a spokesperson said on Tuesday, confirming the contents of a memo sent to dealers and reported on by U.S. trade publication Automotive News. The carmaker has around 37,000 vehicles, sufficient for approximately two...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial
Apr 7, 2025
April 7 (Reuters) - Rhythm Pharmaceuticals ( RYTM ) said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved